Trials / Unknown
UnknownNCT04091789
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
A Controlled-Dose Study Using Cannabinoid Combinations in a Rapidly Dissolvable Sublingual Tablet for the Treatment of Dysmenorrhea and Associated Pain Symptoms
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Pure Green · Industry
- Sex
- Female
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pure Femme Tablets | A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil. |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2020-03-01
- Completion
- 2020-05-01
- First posted
- 2019-09-17
- Last updated
- 2019-09-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04091789. Inclusion in this directory is not an endorsement.